Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

Despite Quest Diagnostics’ strong performance, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 16 analysts covering the ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But ...

Assess today's live Quest Diagnostics orporated (DGX) share price, performance and insights using our live NYSE: DGX stock exchange data. Analyse the historical data and Quest Diagnostics orporated ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Penumbra Inc (NYSE: PEN ): Adam Elsesser, CEO and President, sold shares totaling approximately $4.5 million at prices ranging from $267.36 to $277.63 per share. Elsesser also exercised stock options ...

Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.